Live
FierceBiotechCBER chief Prasad steps aside, deputy takes the reins as search for successor continuesFierceBiotechJ&J axes $5B CAR-T dream months after touting best-in-disease efficacyEndpoints NewsSummit slips on ivonescimab's apparent interim miss in sign of investor frustrationEndpoints NewsAmgen files update to Tavneos label as FDA escalates push to withdrawFierceBiotechChutes & Ladders—Astellas appoints new top strategist from Sanofi JapanFierceBiotechLigand tries to disembark from part of Viking pact, alleging contract breachCellBringing the genetically minimal cell to life on a computer in 4DIlluminaCanaccord cuts Illumina stock price target on competition concerns - Investing.comEndpoints NewsSeaport, Hemab price IPOs, while Avalyn soars in Nasdaq debutThermo FisherIs Thermo Fisher’s New U.S. Bioprocess Design Center Shaping a Deeper Biopharma Strategy for TMO? - simplywall.stEndpoints NewsJ&J axes pair of CAR-T therapies for lymphoma, citing evolving marketEndpoints NewsBoehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit
FierceBiotech May 1, 2026

Ligand tries to disembark from part of Viking pact, alleging contract breach

Ligand tries to disembark from part of Viking pact, alleging contract breach

Original
Body unavailable. Use the original source.